欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2021, Vol. 26 ›› Issue (2): 196-203.doi: 10.12092/j.issn.1009-2501.2021.02.011

• 综述与讲座 • 上一篇    下一篇

肺鳞癌成纤维细胞生长因子受体分子改变及其治疗对策

谢荣容1,陈帜1,杨昱2,谢饶英3,李平平1,孙霜霜1,陈文俊1   

  1. 1温州医科大学附属第二医院肿瘤放化疗科,温州 325000,浙江;2温州市老年病医院肿瘤内科,温州 325000,浙江;3温州医科大学附属第一医院放化疗科,温州 325000,浙江

  • 收稿日期:2020-08-31 修回日期:2021-01-02 出版日期:2021-02-26 发布日期:2021-03-04
  • 通讯作者: 陈文俊,男,主任医师,教授,硕士生导师,研究方向:恶性肿瘤的同步放化疗。 Tel: 0577-88002646 E-mail: cwj2233@126.com
  • 作者简介:谢荣容,女,硕士研究生在读,研究方向:恶性肿瘤的同步放化疗。 Tel: 0577-88002646 E-mail: 841186577@qq.com
  • 基金资助:
    浙江省自然科学基金/青年基金项目(LQ18H070005)

Treatment strategies of FGFR molecular alterations in lung squamous cell carcinoma

XIE Rongrong 1, CHEN Zhi 1, YANG Yu 2, XIE Raoying 3, LI Pingping 1, SUN Shuangshuang 1, CHEN Wenjun1   

  1. 1 Department of Radiotherapy and Chemotherapy of the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China; 2 Department of Medical Oncology of Wenzhou Geriatric Hospital, Wenzhou 325000, Zhejiang, China; 3 Department of Radiotherapy and Chemotherapy of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang, China
  • Received:2020-08-31 Revised:2021-01-02 Online:2021-02-26 Published:2021-03-04

摘要: 肺癌是发病率和死亡率最高的恶性肿瘤。针对肺癌尤其是非鳞非小细胞肺癌的分子靶向治疗发展迅速,取得了较好的治疗效果。研究发现,成纤维细胞生长因子受体(fibroblast growth factor receptor, FGFR)信号通路通过不同的机制促进肿瘤血管生成和支持癌细胞增殖,在多种肿瘤的发生发展中起作用。这提示阻断FGFR信号通路,有可能抑制肿瘤的增殖。研究观察到FGFR途径失调发生于多个恶性肿瘤,其中包括肺鳞癌(lung squamous cell carcinoma, LUSC)。这使得FGFR有希望成为LUSC潜在的药物治疗靶点。本文就该通路在LUSC中的基因改变、作用及其抑制剂作一综述。

关键词: 肺鳞癌, 成纤维细胞生长因子受体, 靶向治疗

Abstract: Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death. Molecular targeted therapy for lung cancer, especially non-squamous non-small cell lung cancer, has developed rapidly and achieved good results. Several studies have found that fibroblast growth factor receptor (FGFR) signaling supports cancer cell proliferation and stimulates angiogenesis through different mechanisms, which plays a role in the development and progression of several tumors. This indicates that the inhibitions of FGFR signaling pathway may inhibit the proliferation of cancer cells. Dysregulation of FGFR signaling has been observed in some types of malignancy, including lung squamous cell carcinoma (LUSC), making FGFR a potential therapeutic target for LUSC. This review focuses on the role of FGFR signaling and some FGFR inhibitors in LUSC.

Key words: lung squamous cell carcinoma, fibroblast growth factor receptor, targeted therapies

中图分类号: